Bhanvi Satija
U.S. Health & Pharma Sector Specialist at Reuters
Covering U.S. Health and Pharma for Reuters. Views expressed are my own. RTs ≠ endorsements. Sporadic Twitter-er.
Articles
-
4 days ago |
autism.einnews.com | Bhanvi Satija |Christy Santhosh
By Bhanvi Satija and Christy Santhosh(Reuters) -The U.S. Centers for Disease Control and Prevention posted a report on Tuesday that said evidence does not support a link between thimerosal-containing vaccines and autism or other neurodevelopmental disorders, ahead of a two-day meeting of an advisory panel later this week. The report was posted on the agency's website on Tuesday, along with some presentations and the final agenda of the meeting, which is scheduled for June 25 and 26.
-
4 days ago |
today.westlaw.com | Shinjini Ganguli |Bhanvi Satija |Sneha K |Bill Berkrot
(Reuters) -A review on the use of the preservative thimerosal in vaccines slated to be presented on Thursday to the U.S. Centers for Disease Control and Prevention's outside vaccine committee cites a study that does not exist, the scientist listed as...
-
1 week ago |
kfgo.com | Bhanvi Satija
By Bhanvi Satija(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday. About a dozen companies are racing to develop such therapies, most of which are being tested in combination with Lilly’s Zepbound or Novo’s Wegovy, both of which target the GLP-1 protein to help control appetite.
-
1 week ago |
timeslive.co.za | Michael Erman |Bhanvi Satija
20 June 2025 - 11:01 Just R20 for the first month. Support independent journalism by subscribing to our digital news package. 'There isn't any doubt that we're in new territory and things are being done differently than they were before,' says William Schaffner, professor of infectious diseases at Vanderbilt University Medical Centre. File photo.
-
1 week ago |
today.westlaw.com | Bhanvi Satija |Mohammed Shamsi
(Reuters) -Treatments designed to help patients preserve muscle while losing weight with popular obesity drugs by Eli Lilly and Novo Nordisk could generate more than $30 billion in sales by 2035, analysts at TD Cowen said on Friday.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 548
- Tweets
- 1K
- DMs Open
- No
RT @appadappajappa: In the next couple of decades, we are going to have a great number of single women in their 30s. Our society is not rea…
RT @Reuters_Health: A World Health Organization official on Thursday called for stronger surveillance in animals for evidence of infection…
RT @Reuters_Health: Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity…